Targeted therapy approved for bladder cancer

atezolizumab (Tecentriq)
avelumab (Bavencio)
enfortumab vedotin-ejfv (Padcev)
erdafitinib (Balversa)
nivolumab (Opdivo)
nogapendekin alfa inbakicept-pmln (Anktiva)
pembrolizumab (Keytruda)
Targeted therapy approved for brain cancer

belzutifan (Welireg)
bevacizumab (Avastin)
dabrafenib (Tafinlar)
everolimus (Afinitor)
tovorafenib (Ojemda)
trametinib (Mekinist)
vorasidenib (Voranigo)
Targeted therapy approved for breast cancer

abemaciclib (Verzenio)
ado-trastuzumab emtansine (Kadcyla)
alpelisib (Piqray)
anastrozole (Arimidex)
capivasertib (Truqap)
datopotamab deruxtecan-dlnk (Datroway)
elacestrant dihydrochloride (Orserdu)
everolimus (Afinitor)
exemestane (Aromasin)
fam-trastuzumab deruxtecan-nxki (Enhertu)
fulvestrant (Faslodex)
goserelin acetate (Zoladex)
inavolisib (Itovebi)
lapatinib ditosylate (Tykerb)
letrozole (Femara)
margetuximab-cmkb (Margenza)
neratinib maleate (Nerlynx)
olaparib (Lynparza)
palbociclib (Ibrance)
pembrolizumab (Keytruda)
pertuzumab (Perjeta)
pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo)
ribociclib (Kisqali)
ribociclib succinate and letrozole (Kisquali Femara Co-Pack)
sacituzumab govitecan-hziy (Trodelvy)
talazoparib tosylate (Talzenna)
tamoxifen citrate (Soltamox)
toremifene (Fareston)
trastuzumab (Herceptin)
tucatinib (Tukysa)
Targeted therapy approved for cervical cancer

bevacizumab (Avastin)
pembrolizumab (Keytruda)
tisotumab vedotin-tftv (Tivdak)
Targeted therapy approved for colorectal cancer

adagrasib (Krazati)
bevacizumab (Avastin)
cetuximab (Erbitux)
encorafenib (Braftovi)
fruquintinib (Fruzalqa)
ipilimumab (Yervoy)
nivolumab (Opdivo)
panitumumab (Vectibix)
pembrolizumab (Keytruda)
ramucirumab (Cyramza)
regorafenib (Stivarga)
sotorasib (Lumakras)
tucatinib (Tukysa)
ziv-aflibercept (Zaltrap)
Targeted therapy approved for dermatofibrosarcoma protuberans

imatinib mesylate (Gleevec)
Targeted therapy approved for endocrine and neuroendocrine tumors

avelumab (Bavencio)
everolimus (Afinitor)
iobenguane I 131 (Azedra)
lanreotide acetate (Somatuline Depot)
lutetium Lu 177-dotatate (Lutathera)
Targeted therapy approved for endometrial cancer

dostarlimab-gxly (Jemperli)
durvalumab (Imfinzi)
lenvatinib mesylate (Lenvima)
pembrolizumab (Keytruda)
Targeted therapy approved for esophageal cancer

fam-trastuzumab deruxtecan-nxki (Enhertu)
ipilimumab (Yervoy)
nivolumab (Opdivo)
pembrolizumab (Keytruda)
ramucirumab (Cyramza)
tislelizumab-jsgr (Tevimbra)
trastuzumab (Herceptin)
zolbetuximab-clzb (Vyloy)
Targeted therapy approved for head and neck cancer

cetuximab (Erbitux)
nivolumab (Opdivo)
pembrolizumab (Keytruda)
toripalimab-tpzi (Loqtorzi)
Targeted therapy approved for gastrointestinal stromal tumor

avapritinib (Ayvakit)
imatinib mesylate (Gleevec)
regorafenib (Stivarga)
ripretinib (Qinlock)
sunitinib malate (Sutent)
Targeted therapy approved for giant cell tumor

denosumab (Xgeva)
pexidartinib hydrochloride (Turalio)
Targeted therapy approved for kidney cancer

avelumab (Bavencio)
axitinib (Inlyta)
belzutifan (Welireg)
bevacizumab (Avastin)
cabozantinib-s-malate (Cabometyx)
everolimus (Afinitor)
ipilimumab (Yervoy)
lenvatinib mesylate (Lenvima)
nivolumab (Opdivo)
pazopanib hydrochloride (Votrient)
pembrolizumab (Keytruda)
sorafenib tosylate (Nexavar)
sunitinib malate (Sutent)
temsirolimus (Torisel)
tivozanib hydrochloride (Fotivda)
Targeted therapy approved for leukemia

acalabrutinib (Calquence)
alemtuzumab (Campath)
asciminib hydrochloride (Scemblix)
avapritinib (Ayvakit)
blinatumomab (Blincyto)
bosutinib (Bosulif)
brexucabtagene autoleucel (Tecartus)
dasatinib (Sprycel)
duvelisib (Copiktra)
enasidenib mesylate (Idhifa)
gemtuzumab ozogamicin (Mylotarg)
gilteritinib fumarate (Xospata)
glasdegib maleate (Daurismo)
ibrutinib (Imbruvica)
idelalisib (Zydelig)
imatinib mesylate (Gleevec)
inotuzumab ozogamicin (Besponsa)
ivosidenib (Tibsovo)
lisocabtagene maraleucel (Breyanzi)
midostaurin (Rydapt)
nilotinib (Tasigna)
obecabtagene autoleucel (Aucatzyl)
obinutuzumab (Gazyva)
ofatumumab (Arzerra)
olutasidenib (Rezlidhia)
pemigatinib (Pemazyre)
pirtobrutinib (Jaypirca)
ponatinib hydrochloride (Iclusig)
quizartinib dihydrochloride (Vanflyta)
revumenib citrate (Revuforj)
rituximab (Rituxan)
rituximab and hyaluronidase human (Rituxan Hycela)
tagraxofusp-erzs (Elzonris)
tisagenlecleucel (Kymriah)
tretinoin (Vesanoid) 
venetoclax (Venclexta)
zanubrutinib (Brukinsa)
Targeted therapy approved for liver and bile duct cancer

atezolizumab (Tecentriq)
atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza)
bevacizumab (Avastin)
cabozantinib-s-malate (Cabometyx)
durvalumab (Imfinzi)
futibatinib (Lytgobi)
ipilimumab (Yervoy)
ivosidenib (Tibsovo)
lenvatinib mesylate (Lenvima)
nivolumab (Opdivo)
pembrolizumab (Keytruda)
pemigatinib (Pemazyre)
ramucirumab (Cyramza)
regorafenib (Stivarga)
sorafenib tosylate (Nexavar)
tremelimumab-actl (Imjudo)
zanidatamab-hrii (Ziihera)
Targeted therapy approved for lung cancer

adagrasib (Krazati)
afatinib dimaleate (Gilotrif)
alectinib (Alecensa)
amivantamab-vmjw (Rybrevant)
atezolizumab (Tecentriq)
atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza)
bevacizumab (Avastin)
binimetinib (Mektovi)
brigatinib (Alunbrig)
capmatinib hydrochloride (Tabrecta)
cemiplimab-rwlc (Libtayo)
ceritinib (Zykadia)
crizotinib (Xalkori)
dabrafenib mesylate (Tafinlar)
dacomitinib (Vizimpro)
durvalumab (Imfinzi)
encorafenib (Braftovi)
entrectinib (Rozlytrek)
erlotinib hydrochloride (Tarceva)
fam-trastuzumab deruxtecan-nxki (Enhertu) 
gefitinib (Iressa)
ipilimumab (Yervoy)
lazertinib mesylate hydrate (Lazcluze)
lorlatinib (Lorbrena)
necitumumab (Portrazza)
nivolumab (Opdivo)
osimertinib mesylate (Tagrisso)
pembrolizumab (Keytruda)
pralsetinib (Gavreto)
ramucirumab (Cyramza)
repotrectinib (Augtyro)
selpercatinib (Retevmo)
sotorasib (Lumakras)
tarlatamab-dlle (Imdelltra)
tepotinib hydrochloride (Tepmetko)
trametinib dimethyl sulfoxide (Mekinist)
tremelimumab-actl (Imjudo)
zenocutuzumab-zbco (Bizengri)
Targeted therapy approved for lymphoma

acalabrutinib maleate monohydrate (Calquence)
axicabtagene ciloleucel (Yescarta)
belinostat (Beleodaq)
bexarotene (Targretin)
bortezomib (Velcade)
brentuximab vedotin (Adcetris)
brexucabtagene autoleucel (Tecartus)
crizotinib (Xalkori)
denileukin diftitox (Lymphir)
duvelisib (Copiktra)
epcoritamab-bysp (Epkinly)
glofitamab-gxbm (Columvi)
ibritumomab tiuxetan (Zevalin)
ibrutinib (Imbruvica)
lisocabtagene maraleucel (Breyanzi)
loncastuximab tesirine-lpyl (Zynlonta)
mogamulizumab-kpkc (Poteligeo)
mosunetuzumab-axgb (Lunsumio)
nivolumab (Opdivo)
obinutuzumab (Gazyva)
pembrolizumab (Keytruda)
pemigatinib (Pemazyre)
pirtobrutinib (Jaypirca)
polatuzumab vedotin-piiq (Polivy)
pralatrexate (Folotyn)
rituximab (Rituxan)
rituximab and hyaluronidase human (Rituxan Hycela)
romidepsin (Istodax)
selinexor (Xpovio)
siltuximab (Sylvant)
tafasitamab-cxix (Monjuvi)
tazemetostat hydrobromide (Tazverik)
tisagenlecleucel (Kymriah)
venetoclax (Venclexta)
vorinostat (Zolinza)
zanubrutinib (Brukinsa)
Targeted therapy approved for malignant mesothelioma

ipilimumab (Yervoy)
nivolumab (Opdivo)
pembrolizumab (Keytruda)
Targeted therapy approved for multiple myeloma

bortezomib (Velcade)
carfilzomib (Kyprolis)
ciltacabtagene autoleucel (Carvykti)
daratumumab (Darzalex)
daratumumab and hyaluronidase-fihj (Darzalex Faspro)
elranatamab-bcmm (Elrexfio)
elotuzumab (Empliciti)
idecabtagene vicleucel (Abecma)
isatuximab-irfc (Sarclisa)
ixazomib citrate (Ninlaro)
talquetamab-tgvs (Talvey)
selinexor (Xpovio)
teclistamab-cqyv (Tecvayli)
Targeted therapy approved for myelodysplastic and myeloproliferative disorders

fedratinib hydrochloride (Inrebic)
imatinib mesylate (Gleevec)
imetelstat sodium (Rytelo)
ivosidenib (Tibsovo)
momelotinib dihydrochloride monohydrate (Ojjaara)
pacritinib citrate (Vonjo)
pemigatinib (Pemazyre)
ruxolitinib phosphate (Jakafi)
Targeted therapy approved for neuroblastoma

dinutuximab (Unituxin)
naxitamab-gqgk (Danyelza)
Targeted therapy approved for ovarian epithelial, fallopian tube, and primary peritoneal cancers

bevacizumab (Avastin)
mirvetuximab soravtansine-gynx (Elahere)
niraparib tosylate monohydrate (Zejula)
olaparib (Lynparza)
rucaparib camsylate (Rubraca)
Targeted therapy approved for pancreatic cancer

belzutifan (Welireg)
erlotinib hydrochloride (Tarceva)
everolimus (Afinitor)
olaparib (Lynparza)
sunitinib malate (Sutent)
zenocutuzumab-zbco (Bizengri)
Targeted therapy approved for plexiform neurofibroma

selumetinib sulfate (Koselugo)
Targeted therapy approved for prostate cancer

abiraterone acetate (Zytiga)
apalutamide (Erleada)
bicalutamide (Casodex)
cabazitaxel (Jevtana)
darolutamide (Nubeqa)
degarelix (Firmagon)
enzalutamide (Xtandi)
flutamide
goserelin acetate (Zoladex)
leuprolide acetate (Lupron Depot, Eligard)
leuprolide mesylate (Camcevi)
lutetium Lu 177 vipivotide tetraxetan (Pluvicto)
nilutamide (Nilandron)
niraparib tosylate monohydrate and abiraterone acetate (Akeega)
olaparib (Lynparza)
talazoparib tosylate (Talzenna)
radium 223 dichloride (Xofigo)
relugolix (Orgovyx)
rucaparib camsylate (Rubraca)
triptorelin pamoate (Trelstar)
Targeted therapy approved for skin cancer

alitretinoin (Panretin)
atezolizumab (Tecentriq)
atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza)
avelumab (Bavencio)
binimetinib (Mektovi)
cemiplimab-rwlc (Libtayo)
cobimetinib fumarate (Cotellic)
dabrafenib mesylate (Tafinlar)
encorafenib (Braftovi)
ipilimumab (Yervoy)
nivolumab (Opdivo)
nivolumab and relatlimab-rmbw (Opdualag)
pembrolizumab (Keytruda)
retifanlimab-dlwr (Zynyz)
sonidegib (Odomzo)
tebentafusp-tebn (Kimmtrak)
trametinib dimethyl sulfoxide (Mekinist)
vismodegib (Erivedge)
vemurafenib (Zelboraf)
Targeted therapy approved for soft tissue sarcoma

afamitresgene autoleucel (Tecelra)
alitretinoin (Panretin)
atezolizumab (Tecentriq)
atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) 
crizotinib (Xalkori)
nirogacestat hydrobromide (Ogsiveo)
pazopanib hydrochloride (Votrient)
sirolimus protein-bound particles (Fyarro)
tazemetostat hydrobromide (Tazverik)
Targeted therapy approved for solid tumors anywhere in the body

dabrafenib mesylate (Tafinlar)
dostarlimab-gxly (Jemperli)
entrectinib (Rozlytrek)
fam-trastuzumab deruxtecan-nxki (Enhertu)
larotrectinib sulfate (Vitrakvi)
pembrolizumab (Keytruda)
repotrectinib (Augtyro)
selpercatinib (Retevmo)
trametinib dimethyl sulfoxide (Mekinist)
Targeted therapy approved for stomach (gastric) cancer

fam-trastuzumab deruxtecan-nxki (Enhertu)
nivolumab (Opdivo)
pembrolizumab (Keytruda)
ramucirumab (Cyramza)
tislelizumab-jsgr (Tevimbra)
trastuzumab (Herceptin)
zolbetuximab-clzb (Vyloy)
Targeted therapy approved for systemic mastocytosis

avapritinib (Ayvakit)
imatinib mesylate (Gleevec)
midostaurin (Rydapt)
Targeted therapy approved for thyroid cancer

cabozantinib-s-malate (Cometriq)
dabrafenib mesylate (Tafinlar)
lenvatinib mesylate (Lenvima)
pralsetinib (Gavreto)
selpercatinib (Retevmo)
sorafenib tosylate (Nexavar)
trametinib dimethyl sulfoxide (Mekinist)
vandetanib (Caprelsa)